1257 related articles for article (PubMed ID: 8413456)
21. Effect of captopril on heavy proteinuria in azotemic diabetics.
Taguma Y; Kitamoto Y; Futaki G; Ueda H; Monma H; Ishizaki M; Takahashi H; Sekino H; Sasaki Y
N Engl J Med; 1985 Dec; 313(26):1617-20. PubMed ID: 3906398
[TBL] [Abstract][Full Text] [Related]
22. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.
Parving HH; Hommel E; Jensen BR; Hansen HP
Kidney Int; 2001 Jul; 60(1):228-34. PubMed ID: 11422755
[TBL] [Abstract][Full Text] [Related]
23. Advanced glycosylation end products in patients with diabetic nephropathy.
Makita Z; Radoff S; Rayfield EJ; Yang Z; Skolnik E; Delaney V; Friedman EA; Cerami A; Vlassara H
N Engl J Med; 1991 Sep; 325(12):836-42. PubMed ID: 1875967
[TBL] [Abstract][Full Text] [Related]
24. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis.
Owen WF; Lew NL; Liu Y; Lowrie EG; Lazarus JM
N Engl J Med; 1993 Sep; 329(14):1001-6. PubMed ID: 8366899
[TBL] [Abstract][Full Text] [Related]
25. Impairment of renal function with increasing blood lead concentrations in the general population. The Cadmibel Study Group.
Staessen JA; Lauwerys RR; Buchet JP; Bulpitt CJ; Rondia D; Vanrenterghem Y; Amery A
N Engl J Med; 1992 Jul; 327(3):151-6. PubMed ID: 1608406
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.
Feutren G; Mihatsch MJ
N Engl J Med; 1992 Jun; 326(25):1654-60. PubMed ID: 1588978
[TBL] [Abstract][Full Text] [Related]
27. Outcome of pregnancy in women with moderate or severe renal insufficiency.
Jones DC; Hayslett JP
N Engl J Med; 1996 Jul; 335(4):226-32. PubMed ID: 8657238
[TBL] [Abstract][Full Text] [Related]
28. Comparison between the effect of glibenclamide and captopril on experimentally induced diabetic nephropathy in rats.
Akbar DH; Hagras MM; Amin HA; Khorshid OA
J Renin Angiotensin Aldosterone Syst; 2013 Jun; 14(2):103-15. PubMed ID: 23077081
[TBL] [Abstract][Full Text] [Related]
29. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group.
Allgren RL; Marbury TC; Rahman SN; Weisberg LS; Fenves AZ; Lafayette RA; Sweet RM; Genter FC; Kurnik BR; Conger JD; Sayegh MH
N Engl J Med; 1997 Mar; 336(12):828-34. PubMed ID: 9062091
[TBL] [Abstract][Full Text] [Related]
30. Nephrotoxic effects in high-risk patients undergoing angiography.
Aspelin P; Aubry P; Fransson SG; Strasser R; Willenbrock R; Berg KJ;
N Engl J Med; 2003 Feb; 348(6):491-9. PubMed ID: 12571256
[TBL] [Abstract][Full Text] [Related]
31. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
Rodby RA; Firth LM; Lewis EJ
Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
[TBL] [Abstract][Full Text] [Related]
32. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy.
Parving HH; Hommel E; Damkjaer Nielsen M; Giese J
BMJ; 1989 Aug; 299(6698):533-6. PubMed ID: 2507061
[TBL] [Abstract][Full Text] [Related]
33. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.
Lewis JB; Berl T; Bain RP; Rohde RD; Lewis EJ
Am J Kidney Dis; 1999 Nov; 34(5):809-17. PubMed ID: 10561135
[TBL] [Abstract][Full Text] [Related]
34. A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: study design and patient characteristics. The Collaborative Study Group.
Bain R; Rohde R; Hunsicker LG; McGill J; Kobrin S; Lewis EJ
J Am Soc Nephrol; 1992 Oct; 3(4 Suppl):S97-103. PubMed ID: 1457767
[TBL] [Abstract][Full Text] [Related]
35. Effects of captopril on diabetic nephropathy in hypertensive women.
Gonzalez-Sicilia de Llamas L; Garcia Alberola A; Lafuente Lopez-Herrera M; Fuente Jimenez T; Fernandez Pardo J; Hernandez Cascales J
Eur J Clin Pharmacol; 1991; 41(5):405-9. PubMed ID: 1761066
[TBL] [Abstract][Full Text] [Related]
36. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases.
Liou HH; Huang TP; Campese VM
Nephron; 1995; 69(1):41-8. PubMed ID: 7891796
[TBL] [Abstract][Full Text] [Related]
37. Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens.
Chen KH; Lin JL; Lin-Tan DT; Hsu HH; Hsu CW; Hsu KH; Yen TH
Am J Kidney Dis; 2012 Oct; 60(4):530-8. PubMed ID: 22721929
[TBL] [Abstract][Full Text] [Related]
38. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.
Wilmer WA; Hebert LA; Lewis EJ; Rohde RD; Whittier F; Cattran D; Levey AS; Lewis JB; Spitalewitz S; Blumenthal S; Bain RP
Am J Kidney Dis; 1999 Aug; 34(2):308-14. PubMed ID: 10430979
[TBL] [Abstract][Full Text] [Related]
39. The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. Collaborative Study Group.
Rodby RA; Rohde R; Evans J; Bain RP; Mulcahy WS; Lewis EJ
J Am Soc Nephrol; 1995 Apr; 5(10):1775-81. PubMed ID: 7787145
[TBL] [Abstract][Full Text] [Related]
40. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group.
Donadio JV; Bergstralh EJ; Offord KP; Spencer DC; Holley KE
N Engl J Med; 1994 Nov; 331(18):1194-9. PubMed ID: 7935657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
